BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29451296)

  • 1. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
    Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
    Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
    Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
    Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
    Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
    Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
    Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
    Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
    Peng J; Chen YT; Chen CL; Li L
    Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
    BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
    Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
    OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
    Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
    PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
    Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
    Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
    Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
    J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
    Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
    PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
    von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
    J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
    Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
    Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary mRNA biomarker panel for the detection of urothelial carcinoma.
    Urquidi V; Netherton M; Gomes-Giacoia E; Serie D; Eckel-Passow J; Rosser CJ; Goodison S
    Oncotarget; 2016 Jun; 7(25):38731-38740. PubMed ID: 27231851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
    Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
    Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-analyte assay for the non-invasive detection of bladder cancer.
    Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
    PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.
    Juracek J; Peltanova B; Dolezel J; Fedorko M; Pacik D; Radova L; Vesela P; Svoboda M; Slaby O; Stanik M
    J Cell Mol Med; 2018 Mar; 22(3):2033-2038. PubMed ID: 29363887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.